Dublin, July 05, 2019 (GLOBE NEWSWIRE) -- The "Indication-level Pricing: Payer Insights" report has been added to ResearchAndMarkets.com's offering.
Can pharma persuade payers of the benefits of indication-level pricing?
Advocates argue that indication-level pricing can bring new products on stream and results in wider patient access to new therapies. That's a good thing, right? Maybe, but for indication-level pricing to work payers would have to overcome a range of practical and costly administrative, data collection and regulatory obstacles.
There is also the perennial payers' suspicion that profit underlies pharma's enthusiasm. Pharma wants optimum price, payers want value and patients need access-but is indication-level pricing a model that is ever likely to deliver at pace and scale, and what can pharma do now to progress the argument for indication-level pricing with payers?
Understanding in detail what payers see as the main issues and areas of objection is critical. That is why, in Indication-level Pricing: Payer Insights, we interviewed experienced payers from the US and Europe to help you evaluate where-and how-pharma can act.
Payers explore indication-level pricing challenges
What to expect
What is indication-level pricing and why is it a problem for payers?
The number of drugs coming to market with more than one indication is increasing, and their value can differ markedly across those indications. A challenge for securing reimbursement can come for companies when they have to operate with a single price regardless of indication.
Where the single price is for the higher-value indication, reimbursement agencies may not recommend use for the lower-value indications with the result that patients won't have access for that indication. Where the single price is for a lower-value indication, companies will be dis-incentivised from developing higher-value indications.
Most countries have a unique price, set at launch, and payers make a yes or no decision for each new indication. Pharma want price to reflect value but is indication-level pricing the model that will deliver?
Sources / Contributors
For more information about this report visit https://www.researchandmarkets.com/r/eq2eel
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Pharmaceutical Manufacturing